New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
17:41 EDTVRX, HES, WLL, WFT, BHIPoint72 Asset Management gives quarterly update on stakes
NEW STAKES: Baker Hughes (BHI), Whiting Petroleum (WLL), Valeant (VRX), Weatherford (WFT), and Hess (HES).
News For BHI;WLL;VRX;WFT;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 21, 2015
08:09 EDTBHIBaker Hughes expects unfavorable market dynamics to persist in 2H15
Subscribe for More Information
08:08 EDTBHIBaker Hughes says Q2 negatively impacted by deteriorating pricing, currency
CEO Martin Craighead commented, "Even though the severity of the revenue decline has compressed our margins, we have minimized the impact by aggressively reducing costs and rightsizing our operational footprint. These actions have resulted in decremental margins of 35% compared to the prior year, a significant improvement from the prior industry downturn. Furthermore, earnings for the quarter were impacted by an unfavorable tax rate which resulted primarily from a change in the geographic mix of earnings."
08:07 EDTBHIBaker Hughes reports Q2 adjusted EPS (14c), consensus (13c)
Subscribe for More Information
07:20 EDTBHIHalliburton has 90% upside potential over 3 years, says Citi
Citi analyst Scott Gruber believes regulatory approval for Halliburton's (HAL) proposed acquisition of Baker Hughes (BHI) is a "high probability event." Halliburton's buyback potential post-acquisition looks significant, Gruber tells investors in a research note. He estimates $5.00 of pro forma earnings per share for Halliburton in 2018, suggesting 90% upside potential for shares over the next three years. The analyst notes that applying a 16 times earnings multiple yields a $78 share price. He keeps a Buy rating on Halliburton with a $54 price target. The oil services company closed yesterday up 75c to $40.74 after reporting Q2 results.
July 20, 2015
16:15 EDTVRXValeant initiated with a Buy at BTIG
Subscribe for More Information
15:01 EDTBHINotable companies reporting before tomorrow's open
Subscribe for More Information
10:00 EDTWLLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:38 EDTVRXAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:34 EDTWLLWhiting Petroleum upgraded to Positive at Susquehanna
Subscribe for More Information
07:33 EDTVRXValeant price target raised to $285 from $275 at Canaccord
Subscribe for More Information
07:04 EDTBHIHalliburton incurred $67M after-tax for costs related to Baker Hughes deal in Q2
Subscribe for More Information
07:03 EDTBHIHalliburton says 'pleased' with progress of Baker Hughes acquisiton
Subscribe for More Information
07:00 EDTWLLWhiting Petroleum upgraded to Positive from Neutral at Susquehanna
July 17, 2015
13:03 EDTBHIBaker Hughes reports U.S. rig count down 6 to 857 rigs
Subscribe for More Information
10:00 EDTBHISchlumberger CEO says Halliburton deal creating 'uncertainty' for customers
Subscribe for More Information
09:14 EDTWLLWhiting Petroleum reports $185M of additional non-core property sales
During the second quarter 2015, Whiting sold two packages of older, conventional, operated and non-operated properties to private buyers for a total of $185 million. The effective date for both sales is June 1, 2015 and both sales closed in June 2015. Reserves totaled an estimated 18.0 MMBOE with estimated remaining 2015 production of 6,100 BOE/d. The sales were consistent with Whiting’s continuing 2015 plans to sell mature properties with higher LOE per BOE than its core Bakken and Niobrara assets. LOE for the properties averaged approximately $18.00 per BOE versus $6.50 per BOE in the Bakken and $7.50 per BOE in the Niobrara. Including $108 million of non-core property sales announced in Whiting’s first quarter 2015 financial and operating results press release, year-to-date Whiting has completed a total of $293 million of non-core asset sales with associated reserves of 26.2 MMBOE and estimated remaining 2015 production of 8,300 BOE/d as of the effective dates of each sale. During the second quarter Whiting received $6.0 million in proceeds from fees and an approximate proportionately reduced 5% overriding royalty interest from the sale of its working interest in select non-operated wellbores in the Bakken/Three Forks play in the Williston Basin. The company sold these non-operated wellbores to concentrate its capital in its most efficient and profitable operated drilling prospects. Including this transaction, year-to-date Whiting has completed $300 million in asset sales.
09:06 EDTWLLWhiting estimates 1H15 capital expenditures $1.59B
Whiting estimates 1H 2015 capital expenditures totaled $1.59B. In the first half of the year, The company incurred $211M of non-operated drilling expenditures. The company has entered into an agreement to monetize the majority of its non-operated drilling through the remainder of 2015 to concentrate capital in the most profitable operated drilling prospects and project only $42M of non-operated capex in the second half of 2015.
09:04 EDTWLLWhiting sees FY15 production 59.7 MMBOE, up 7%
Subscribe for More Information
09:03 EDTWLLWhiting Petroleum estimates Q2 production 15.5M MMBOE, up 2%
Subscribe for More Information
08:02 EDTVRXValeant agrees to acquire Amoun Pharmaceutical
Valeant announced that it has entered into a definitive agreement under which Valeant will acquire Mercury Holdings, the holding company of Amoun Pharmaceutical, for consideration of approximately $800M, plus contingent payments. Amoun Pharmaceutical currently expects to reach EGP 1.75B by 2015, with annual growth of approximately 20%. Valeant intends for Amoun to serve as a platform for further expansion in the broader Middle East and North Africa pharmaceutical market and expects the transaction to close in the third quarter, subject to customary closing conditions.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use